liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Vasculitis and Lupus Clinic, Renal Unit, Addenbrooke’s Hospital, Cambridge, UK.
Division of Clinical and Experimental Immunology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands .
ImmunologieZentrum Zürich and University Hospital, Zurich, Switzerland .
Department of Rheumatology, Nuffield Orthopaedic Centre, Oxford , UK.
Show others and affiliations
2010 (English)In: New England Journal of Medicine, ISSN 0028-4793, Vol. 363, no 3, 211-220 p.Article in journal (Refereed) Published
Abstract [en]


Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis are effective in 70 to 90% of patients, but they are associated with high rates of death and adverse events. Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens.


We compared rituximab with cyclophosphamide as induction therapy in ANCA-associated vasculitis. We randomly assigned, in a 3:1 ratio, 44 patients with newly diagnosed ANCA-associated vasculitis and renal involvement to a standard glucocorticoid regimen plus either rituximab at a dose of 375 mg per square meter of body-surface area per week for 4 weeks, with two intravenous cyclophosphamide pulses (33 patients, the rituximab group), or intravenous cyclophosphamide for 3 to 6 months followed by azathioprine (11 patients, the control group). Primary end points were sustained remission rates at 12 months and severe adverse events.


The median age was 68 years, and the glomerular filtration rate (GFR) was 18 ml per minute per 1.73 m2 of body-surface area. A total of 25 patients in the rituximab group (76%) and 9 patients in the control group (82%) had a sustained remission (P=0.68). Severe adverse events occurred in 14 patients in the rituximab group (42%) and 4 patients in the control group (36%) (P=0.77). Six of the 33 patients in the rituximab group (18%) and 2 of the 11 patients in the control group (18%) died (P=1.00). The median increase in the GFR between 0 and 12 months was 19 ml per minute in the rituximab group and 15 ml per minute in the control group (P=0.14).


A rituximab-based regimen was not superior to standard intravenous cyclophosphamide for severe ANCA-associated vasculitis. Sustained-remission rates were high in both groups, and the rituximab-based regimen was not associated with reductions in early severe adverse events.

Place, publisher, year, edition, pages
Boston, MA, USA: Massachusetts Medical Society , 2010. Vol. 363, no 3, 211-220 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-101580DOI: 10.1056/NEJMoa0909169ISI: 000279864200004OAI: diva2:666547
Available from: 2013-11-22 Created: 2013-11-22 Last updated: 2014-02-28Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Segelmark, Mårten
By organisation
Division of Drug ResearchFaculty of Health SciencesDepartment of Nephrology
In the same journal
New England Journal of Medicine
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 346 hits
ReferencesLink to record
Permanent link

Direct link